NCT07388745 ESPB vs SPSIP for Postoperative Analgesia After CABG
| NCT ID | NCT07388745 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kutahya Health Sciences University |
| Condition | Coronary Arterial Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2026-03-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized, active-controlled, double-blind, parallel-group study compares the postoperative analgesic efficacy and safety of ultrasound-guided bilateral Erector Spinae Plane Block (ESPB) versus bilateral Serratus Posterior Superior Intercostal Plane Block (SPSIPB) in adult patients (45-85 years, ASA I-III) undergoing elective coronary artery bypass graft surgery. The primary outcome is postoperative pain intensity assessed by Numeric Rating Scale (NRS) at 2, 4, 8, 16, 24, and 48 hours after surgery. Secondary outcomes include intraoperative fentanyl/remifentanil consumption, postoperative morphine consumption, patient-controlled analgesia (PCA) demand/delivery parameters (if PCA is used), need for rescue analgesics, extubation and mobilization times, peak inspiratory flow measured by incentive spirometry at predefined time points, ICU and hospital length of stay, recovery quality (QoR-15 at 0, 24, and 48 hours), mortality, and block-related adverse events.
Eligibility Criteria
Inclusion Criteria: * Age 45-85 years * Scheduled for elective coronary artery bypass graft (CABG) surgery * American Society of Anesthesiologists (ASA) I-II-III * Patients who provide written informed consent and agree to participate in the study Exclusion Criteria: * Emergency cases * ASA IV-V * Known allergy to local anesthetics * Coagulopathy (platelet count \<100,000/mm³, INR \>1.5, aPTT \>1.5× normal) * Infection at the block injection site * Pregnancy * Patients who do not provide written informed consent or decline to participate after being informed
Contact & Investigator
Merve Yaman, Assistant Professor
PRINCIPAL INVESTIGATOR
Kütahya Health Sciences University
Frequently Asked Questions
Who can join the NCT07388745 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 85 Years, studying Coronary Arterial Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07388745 currently recruiting?
Yes, NCT07388745 is actively recruiting participants. Contact the research team at merve.yaman@ksbu.edu.tr for enrollment information.
Where is the NCT07388745 trial being conducted?
This trial is being conducted at Kütahya, Turkey (Türkiye).
Who is sponsoring the NCT07388745 clinical trial?
NCT07388745 is sponsored by Kutahya Health Sciences University. The principal investigator is Merve Yaman, Assistant Professor at Kütahya Health Sciences University. The trial plans to enroll 64 participants.